Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation

 Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation

Bayer Plans Two P-III Studies to Evaluate Aflibercept 8mg Formulation

Shots:

  • The two P-III studies, PHOTON and PULSAR will assess aflibercept 8mg formulation for intravitreal injection in adults with visual impairment due to DME & wet AMD respectively for 12wks with their expected initiation in 2020
  • In 2006, the companies collaborated for aflibercept, under which Regeneron retains rights to Eylea (aflibercept, 2mg) in the US while Bayer has exclusive commercial right outside the US with 50/50 profit sharing, except for Japan where Regeneron received a percentage of total sales
  • Aflibercept solution for injection is a recombinant fusion protein, consisting of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for IVT

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Bayer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post